Akt特异性抑制剂MK2206诱导U937及RS4;11细胞凋亡及其机制

详细信息    查看全文 | 推荐本文 |

英文篇名：Inducing Effect of Akt Kinase Inhibitor MK2206 on Apoptosis in U937 Cells and RS4;11 Cells,and Its Mechanism 作者：周俊 ; 曹江 ; 孟凡静 ; 冯浩 ; 徐开林 英文作者：ZHOU Jun;CAO Jiang;MENG Fan-Jing;FENG Hao;XU Kai-Lin;Department of Hematology,The Affiliated Hospital of Xuzhou Medical College;Transplantation Immunology Laboratory of Xuzhou Medical College; 关键词：MK2206 ; 白血病 ; U937细胞 ; RS4 ; 11细胞 ; 细胞凋亡 英文关键词：MK2206;;leukemia;;U937 cell;;RS4;;11 cell;;apoptosis 中文刊名：XYSY 英文刊名：Journal of Experimental Hematology 机构：徐州医学院附属医院血液科;徐州医学院移植免疫实验室; 出版日期：2015-06-20 出版单位：中国实验血液学杂志 年：2015 期：v.23;No.115 基金：国家自然科学基金(81100349);; 江苏省"六大人才高峰"项目(2011-WS-067) 语种：中文; 页：XYSY201503008 页数：6 CN：03 ISSN：11-4423/R 分类号：35-40

摘要

目的:本研究探讨Akt激酶抑制剂MK2206对U937及RS4;11细胞增殖、凋亡的影响,并分析其可能的作用机制。方法:以不同浓度MK2206处理U937及RS4;11细胞24、48 h,用CCK-8法绘制细胞增殖曲线;Annexin V/7-氨基放线菌素D(7-AAD)双标记法分析细胞凋亡情况;流式细胞术检测细胞周期的变化;实时定量PCR检测Bax、Bcl-2、XIAP、CDK1、caspase-3基因mRNA表达的变化。结果:MK2206对U937及RS4;11细胞增殖具有抑制作用,且抑制效应呈一定的时间和剂量依赖性,U937细胞24、48 h的半数抑制浓度(IC50)分别为(0.48±0.15)和(0.09±0.01)μmol/L,RS4;11细胞24、48 h的半数抑制浓度(IC50)分别为(0.91±0.02)和(0.68±0.11)μmol/L。0.5μmol/L MK2206作用于U937细胞及1.0μmol/L MK2206作用于RS4;11细胞24 h、48 h,Annexin V/7-AAD标记的阳性细胞升高,U937细胞组24 h细胞凋亡率为(4.18±0.70)%,48 h细胞凋亡率为(22.53±4.67)%,均高于对照组的(1.35±0.34)%(P<0.05),且48 h细胞凋亡率较24 h更为明显(P<0.05);RS4;11细胞组24 h和48 h细胞凋亡率分别为(5.74±0.58)%和(10.07±1.24)%,均高于对照组的(1.32±0.31)%(P<0.05),且48 h细胞凋亡率较24 h更为明显(P<0.05)。流式细胞术检测细胞周期结果显示,U937细胞组G2/M期细胞比例为(96.78±9.11)%,高于对照组的(9.64±0.91)%(P<0.05);RS4;11细胞组G2/M期细胞比例为(14.19±3.82)%,高于对照组的(5.75±1.28)%(P<0.05)。荧光定量PCR检测结果示,两种细胞中Bax、caspase-3 mRNA相对表达水平升高,而Bcl-2、XIAP表达水平降低,同时伴CDK1 mRNA水平的减少,与各自对照组相比差异有统计学意义(P<0.05)。结论:MK2206能有效抑制U937及RS4;11细胞增殖及促进细胞凋亡,使细胞周期阻滞于G2/M期,其促凋亡机制与上调Bax与caspase-3基因表达、下调Bcl-2与XIAP基因表达有关,细胞周期G2/M期阻滞与CDK1基因表达水平下降有关。
        Objective:This study was purposed to investigate the effect of Akt kinase inhibitor MK2206 on proliferation and apoptosis of U937 cells and RS4;11 cells,and to explore its possible mechanism.Methods:U937 and RS4;11cells were cultured with different concentrations of MK2206 for 24 h and 48 h,and cell growth curve was analyzed by CCK-8;cell apoptosis was analyzed by Annexin V/7-AAD double labeling;cell cycle changes were analyzed by flow cytometry.The BAX,BCL-2,XIAP,CDK1,caspase-3 mRNA expressions were determined by real time PCR.Results:MK2206 significantly inhibited the growth of U937 and RS4;11 cells in a time-and dose-dependent manner,and the IC_(50)values of U937 cells for 24 h and 48 h were(0.48 ±0.15) μmol/L and(0.09 ±0.01) μmol/L respectively,while IC_(50)values of RS4;11 cells for 24 h and 48 h were(0.91 ± 0.02) μmol/L and(0.68 ± 0.11) μmol/L respectively.U937 were cultured with 0.5 μmol/L MK2206 and RS4;11 cells were cultured with 1.0 μmol/L MK2206 for 24 h and 48 h,and the both apoptosis rates were higher for 24 h or 48 h than that in control group(P < 0.05),meanwhile the apoptosis rates for 48 h were higher than 24 h.The results of cell cycle detection showed that the both cells were arrested in G_2/M phase compared with control group.The real time PCR assay revealed that the expressions of BAX caspase-3 mRNA in cells treated with MK2206 were increased,while BCL-2 XIAP PDK1 were reduced compared with control group.Conclusion:MK2206 can inhibit proliferation and induce apoptosis of U937 and RS4;11 cells,and the both cells are arrested in G_2/M phase.The mechanism of promoting apoptosis may be related with up-regulating BAX,caspase-3 and down-regulating BCL-2,XIAP,meanwhile the cell cycle arrested in G_2/M phase may be associated with down-regulating CDK1.

引文

1 Datta SR,Brunet A,Greenberg ME.Cellular survival:a play in three Akts.Genes Dev,1999;13(22):2905-2927.
    2 Carnero A,Blanco-Aparicio C,Renner O,et al.The PTEN/PI3K/AKT signaling pathway in cancer,therapeutic implications.Curr Cancer Drug Targets,2008;8(3):187-198.
    3 Li X1,Yang Q,Yu H,et al.LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-m TOR pathway.Oncotarget,2014;5(3):788-801.
    4 Ko YH,Miyake H,Behnsawy HM,et al.Limited Significance of Activated Akt-Mammalian Target of Rapamycin Signaling Pathway in Prostate Cancer Progression.Urol Int,2014;93(2):146-151.
    5 Agarwal E,Chaudhuri A,Leiphrakpam PD,et al.Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.BMC Cancer,2014;14(1):145.
    6 Piovan E,Yu J,Tosello V,Herranz D,et al.Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.Cancer Cell,2013;24(6):766-776.
    7 Bradford LS,Rauh-Hain A,Clark RM,et al.Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/m TOR signaling pathway in endometrial cancer.Gyneco Oncol,2014;133(2):346-352.
    8 陈宏浦,黄轶群,马旭东.LY294002对Jeko-1细胞的增殖抑制及作用机制研究.中国实验血液学杂志,2013;21(5):1183-1186.
    9 于文俊,杨文华,杨向东,等.蝎毒多肽提取物对K562细胞PI3K和p-Akt信号蛋白表达及细胞增殖的影响.中国实验血液学杂志,2012;20(4):872-875.
    10 Yap TA,Yan L,Patnaik A,et al.First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol,2011;29(35):4688-4695.
    11 Konopleva MY,Walter RB,Faderl SH,et al.Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor,MK-2206,for the Treatment of Acute Myelogenous Leukemia.Clin Cancer Res,2014;20(8):2226-2235.
    12 Breckenridge DG,Xue D.Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases.Curr Opin Cell Biol,2004;16(6):647-652.
    13 Wright ME,Han DK,Hockenbery DM.Caspase-3 and inhibitor of apoptosis protein(s)interactions in Saccharomyces cerevisiae and mammalian cells.FEBS Lett,2000;481(1):13-18.